To combat the growing problem of antibiotic resistant bacteria, Stanford researchers have developed nanoclusters comprising a metallic core conjugated to a nucleotide.
Stanford inventors have developed an information theoretic, seizure detection algorithm for electroencephalography (EEG) towards improving diagnosis, management, and treatment of patients with epilepsy.
Targeted protein degradation is an emerging strategy for the elimination of classically undruggable proteins. Mucins are known to be involved in tumor-progressive pathways but are difficult to target using small molecules and antibodies.
Researchers at Stanford have developed a novel cell-free stem cell derived extracellular vesicle (EV) therapy powered by pulsed focused ultrasound (pFUS) that enhances its therapeutic and bioenergetic effect.
Stanford scientists have invented a new suite of adaptable hydrogel biomaterials that are optically transparent and injectable for cell encapsulation, tissue engineering, and drug delivery.
The Hu Lab at Stanford has developed a neuroprotective gene therapy for treating glaucoma and other optic neuropathies. Their gene therapy AAV vector expresses NMNAT2 operably linked to a retinal ganglion cell-specific promoter (mSngc).
Colorectal cancer affects 1.4 million new patients annually, with existing treatments often ineffective. A key factor in treatment resistance is high aldehyde dehydrogenase activity, which undermines several chemotherapies.
A team of Stanford engineers has identified first-in-class epidermal growth factor (EGF) mutants with enhanced activity. These mutants can stimulate increased EGF receptor activation at 10-fold lower concentrations than wild-type EGF.
Stanford scientists have developed a neuroprotective, adeno-associated virus (AAV) gene therapy vector that expresses a mutant form of HDAC4 or a fragment of HDAC4 with novel applications to retinal and neurologic diseases, including glaucoma and other retinal ganglion cell di